RT Journal Article
SR Electronic
T1 Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation
JF JACC: Cardiovascular Interventions
FD American College of Cardiology
SP 1189
OP 1198
DO 10.1016/j.jcin.2017.04.019
VO 10
IS 12
A1 Nakamura, Masato
A1 Iijima, Raisuke
A1 Ako, Junya
A1 Shinke, Toshiro
A1 Okada, Hisayuki
A1 Ito, Yoshiaki
A1 Ando, Kenji
A1 Anzai, Hitoshi
A1 Tanaka, Hiroyuki
A1 Ueda, Yasunori
A1 Takiuchi, Shin
A1 Nishida, Yasunori
A1 Ohira, Hiroshi
A1 Kawaguchi, Katsuhiro
A1 Kadotani, Makoto
A1 Niinuma, Hiroyuki
A1 Omiya, Kazuto
A1 Morita, Takashi
A1 Zen, Kan
A1 Yasaka, Yoshinori
A1 Inoue, Kenji
A1 Ishiwata, Sugao
A1 Ochiai, Masahiko
A1 Hamasaki, Toshimitsu
A1 Yokoi, Hiroyoshi
A1 ,
A1 Okada, Hisayuki
A1 Ito, Yoshiaki
A1 Hara, Hidehiko
A1 Ando, Kenji
A1 Anzai, Hitoshi
A1 Tanaka, Hiroyuki
A1 Ueda, Yasunori
A1 Takiuchi, Shin
A1 Nishida, Yasunori
A1 Ohira, Hiroshi
A1 Kawaguchi, Katsuhiro
A1 Kadotani, Makoto
A1 Niinuma, Hiroyuki
A1 Omiya, Kazuto
A1 Morita, Takashi
A1 Zen, Kan
A1 Yaita, Yoshinori
A1 Inoue, Kenji
A1 Ishiwata, Sugao
A1 Ochiai, Masahiko
A1 Takamisawa, Itaru
A1 Yajima, Junji
A1 Ishihara, Takayuki
A1 Nakamura, Shigeru
A1 Fujii, Kenshi
A1 Ashida, Kazuhiro
A1 Ota, Hiroshi
A1 Okutsu, Masaaki
A1 Oshima, Masao
A1 Kongoji, Ken
A1 Jinno, Yasushi
A1 Shutta, Ryu
A1 Shiode, Nobuo
A1 Oumi, Tetsuo
A1 Doijiri, Tatsuki
A1 Yokoi, Yoshiaki
A1 Ogawa, Takayuki
A1 Kimura, Keizo
A1 Munemasa, Mitsuru
A1 Mukawa, Hiroaki
A1 Komiyama, Kota
A1 Suzuki, Takeshi
A1 Inoue, Takumi
A1 Ueno, Takafumi
A1 Sugano, Teruyasu
A1 Yamashita, Jun
A1 Yasumura, Yoshio
A1 Ogawa, Takayuki
A1 Kamiya, Haruo
A1 Fujita, Hiroshi
A1 Shinke, Toshiro
A1 Urasawa, Kazushi
A1 Ono, Shiro
A1 Ajioka, Masayoshi
A1 Ando, Jiro
A1 Mizuno, Koichi
A1 Hirayama, Haruo
A1 Tojo, Taiki
A1 Maekawa, Yuichiro
A1 Kawasaki, Tomohiro
A1 Okamura, Takayuki
A1 Toyota, Fumitoshi
A1 Hikichi, Yutaka
A1 Michishita, Ichiro
A1 Yagi, Takafumi
A1 Kamihata, Hiroshi
A1 Shindo, Naohisa
A1 Ishizaka, Nobukazu
A1 Ashikaga, Takashi
A1 Ozaki, Yukio
A1 Hara, Hisao
A1 Sakamoto, Hiroshi
A1 Kada, Kenji
A1 Doi, Naofumi
A1 Honye, Junko
A1 Yokoi, Hiroyoshi
A1 Takano, Hitoshi
A1 Kawata, Masahito
A1 Houzawa, Hidenori
A1 Ozawa, Toru
A1 Kikuchi, Arifumi
A1 Kadota, Kazushige
A1 Kijima, Yoichi
A1 Ikemoto, Tomokazu
A1 Shimada, Yoshihisa
A1 Yumoto, Kazuhiko
A1 Kawajiri, Kenji
A1 Nozaki, Yoichi
A1 Sakakibara, Masayoshi
A1 Tosaka, Atsushi
A1 Noma, Shigetaka
A1 Wakabayashi, Yasushi
A1 Okada, Masaharu
A1 Hirose, Mizuki
A1 Takagi, Yuichiro
A1 Takagi, Takuro
A1 Miyauchi, Katsumi
A1 Misu, Kazuhiko
A1 Yasuda, Satoshi
A1 Yoshikawa, Ryohei
A1 Inoue, Ichiro
A1 Yoshiyama, Minoru
A1 Masuyama, Toru
A1 Tomobuchi, Yoshiaki
A1 Yamazaki, Seiji
A1 Tanabe, Kengo
A1 Wagatsuma, Kenji
A1 Kato, Masayuki
A1 Kawai, Kazuya
A1 Hamazaki, Yuji
A1 Yamagishi, Masakazu
A1 Shibata, Yoshisato
A1 Watanabe, Kouki
A1 Tachibana, Koichi
A1 Wada, Hiroshi
A1 Ninomiya, Kenji
A1 Suzuki, Hiroshi
A1 Yoshioka, Jiro
A1 Mori, Chikara
A1 Sonoda, Masahiro
A1 Kataoka, Toru
A1 Terai, Hidenobu
A1 Onishi, Yuko
A1 Toma, Masanao
A1 Serikawa, Takeshi
A1 Otsuka, Yoritaka
A1 Yano, Shoji
A1 Ebisawa, Soichiro
A1 Takashima, Hiroaki
A1 Shimomura, Hideki
A1 Kurumatani, Yoko
A1 Sonoda, Shinjo
A1 Uehara, Hiroki
YR 2017
UL http://interventions.onlinejacc.org/content/10/12/1189.abstract
AB Objectives The NIPPON (Nobori Dual Antiplatelet Therapy as Appropriate Duration) study was a multicenter randomized investigation of the noninferiority of short-term versus long-term dual antiplatelet therapy (DAPT) in patients with implantation of the Nobori drug-eluting stent (DES) (Terumo, Tokyo, Japan), which has a biodegradable abluminal coating.Background The optimum duration of DAPT for patients with a biodegradable polymer-coated DES is unclear.Methods The subjects were 3,773 patients with stable or acute coronary syndromes undergoing Nobori stent implantation. They were randomized 1:1 to receive DAPT for 6 or 18 months. The primary endpoint was net adverse clinical and cerebrovascular events (NACCE) (all-cause mortality, myocardial infarction, stroke, and major bleeding) from 6 to 18 months after stenting. Intention-to-treat analysis was performed in 3,307 patients who were followed for at least 6 months.Results NACCE occurred in 34 patients (2.1%) receiving short-term DAPT and 24 patients (1.5%) receiving long-term DAPT (difference 0.6%, 95% confidence interval [CI]: 1.5 to 0.3). Because the lower limit of the 95% CI was inside the specified margin of −2%, noninferiority of short-term DAPT was confirmed. Mortality was 1.0% with short-term DAPT versus 0.4% with long-term DAPT, whereas myocardial infarction was 0.2% versus 0.1%, and major bleeding was 0.7% versus 0.7%, respectively. The estimated probability of NACCE was lower in the long-term DAPT group (hazard ratio: 1.44, 95% CI: 0.86 to 2.43).Conclusions Six months of DAPT was not inferior to 18 months of DAPT following implantation of a DES with a biodegradable abluminal coating. However, this result needs to be interpreted with caution given the open-label design and wide noninferiority margin of the present study. (Nobori Dual Antiplatelet Therapy as Appropriate Duration [NIPPON]; NCT01514227)